Year-end Sale % OFF 
Abstract
Stimulant medications are a central component of management for youth with attention deficit hyperactivity disorder (ADHD) and their access has been impacted by supply shortages since 2022. Disruptions to treatment can lead to increased morbidity and mortality for youth with ADHD. Factors that contribute to pharmaceutical supply chain shortages include surges in demand, reduced capacity for production or distribution, and failures in coordination. This paper provides an overview of the recent stimulant medication shortage and leverages a framework for building resilience in the supply chain to help pediatric health providers take action and improve health outcomes for for youth with ADHD and their families.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
